OBJECTIVE: To compare the cost-effectiveness of fine-needle aspiration biopsy, iodine 131 scintigraphy, and ultrasonography for the initial diagnostic workup of a solitary palpable thyroid nodule. DESIGN: A deterministic cost-effectiveness analysis was conducted using a decision tree to model the diagnostic strategies. SETTING: A single, mid-Atlantic academic medical center. MAIN OUTCOME MEASURES: Expected costs, expected number of cases correctly diagnosed, and incremental cost per additional case correctly diagnosed. RESULTS: Relative to the routine use of fine-needle aspiration biopsy, the incremental cost per case correctly diagnosed is 24,554 dollars for the iodine 131 scintigraphy strategy and 1212 dollars for the ultrasound strategy. CONCLUSIONS: A diagnostic strategy using initial fine-needle aspiration biopsy for palpable thyroid nodules was found to be cost-effective compared with the other approaches as long as a payor's willingness to pay for an additional correct diagnosis is less than 1212 dollars. Prospective studies are needed to validate these finding in clinical practice.
OBJECTIVE: To compare the cost-effectiveness of fine-needle aspiration biopsy, iodine 131 scintigraphy, and ultrasonography for the initial diagnostic workup of a solitary palpable thyroid nodule. DESIGN: A deterministic cost-effectiveness analysis was conducted using a decision tree to model the diagnostic strategies. SETTING: A single, mid-Atlantic academic medical center. MAIN OUTCOME MEASURES: Expected costs, expected number of cases correctly diagnosed, and incremental cost per additional case correctly diagnosed. RESULTS: Relative to the routine use of fine-needle aspiration biopsy, the incremental cost per case correctly diagnosed is 24,554 dollars for the iodine 131 scintigraphy strategy and 1212 dollars for the ultrasound strategy. CONCLUSIONS: A diagnostic strategy using initial fine-needle aspiration biopsy for palpable thyroid nodules was found to be cost-effective compared with the other approaches as long as a payor's willingness to pay for an additional correct diagnosis is less than 1212 dollars. Prospective studies are needed to validate these finding in clinical practice.
Authors: Mi-Jung Lee; Soon Won Hong; Woung Youn Chung; Jin Young Kwak; Min Jung Kim; Eun-Kyung Kim Journal: Yonsei Med J Date: 2011-09 Impact factor: 2.759